| Market Capitalization (Millions $) |
125 |
| Shares
Outstanding (Millions) |
47 |
| Employees |
99 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-127 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
0 |
Kinnate Biopharma Inc
Kinnate Biopharma Inc is a clinical-stage biopharmaceutical company that specializes in discovering and developing precision medicine therapies. The company is based in San Diego, California and was founded in 2016 by a team of experts in genomic research, cancer biology, and drug discovery.
The focus of Kinnate Biopharma is on developing targeted therapies for genetically defined cancers. The company's approach is to use cutting-edge genomic sequencing and data analysis technologies to identify genetic mutations and aberrations that drive cancer growth. They then develop small molecule drugs that target these specific mutations and are tailored to individual patients' genetic profiles.
Kinnate Biopharma's proprietary platform is called "KinnPlatform," which enables the rapid discovery and development of new cancer therapies. KinnPlatform integrates genomic sequencing, bioinformatics, and advanced chemistry to identify and develop compounds that precisely target oncogenic mutations. The platform is optimized to deliver differentiated, best-in-class products and enables the discovery of new treatments for cancers with high unmet medical needs.
Kinnate Biopharma's pipeline includes several small molecule therapies targeting specific genetic mutations found in various cancer types. Their lead program, KIN0029454, is a precision medicine drug candidate targeting BRAF fusions and mutations, which are found in a range of malignancies, including non-small cell lung cancer, colorectal cancer, and melanoma. According to the company, the drug has demonstrated promising preclinical activity and has received FDA orphan drug designation.
In addition to their lead program, Kinnate Biopharma has several other preclinical programs targeting genetic mutations in other tumor types, including KRAS G12C, NTRK fusion, and ERBB2 mutations. The company's drug discovery efforts are supported by a robust research and development team, including scientists with deep expertise in oncology biology, medicinal chemistry, and drug development.
Kinnate Biopharma has received significant funding from venture capital firms, including OrbiMed and Foresite Capital, as well as strategic partnerships with companies such as Boehringer Ingelheim and Nextech Invest. The company's mission is to improve patient outcomes and positively impact the cancer treatment landscape by developing precise and effective therapies for genetically defined cancers.
Company Address: 800 West El Camino Real, Suite 180 Mountain View 94040 CA
Company Phone Number: 299-4699 Stock Exchange / Ticker: NASDAQ KNTE
|
6.37%